Use of genetic polymorphisms that associate with efficacy of treatment of inflammatory disease

Details for Australian Patent Application No. 2004283235 (hide)

Owner Novartis AG

Inventors McCullough, Karen; Lavedan, Christian Nicolas; Ide, Susan

Agent Davies Collison Cave

Pub. Number AU-B-2004283235

PCT Pub. Number WO2005/040416

Priority 60/508,971 06.10.03 US

Filing date 5 October 2004

Wipo publication date 6 May 2005

Acceptance publication date 2 August 2007

International Classifications

A61K 49/00 (2006.01) Preparations for testing

C12Q 1/68 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving nucleic acids

Event Publications

13 April 2006 PCT application entered the National Phase

  PCT publication WO2005/040416 Priority application(s): WO2005/040416

2 August 2007 Application Accepted

  Published as AU-B-2004283235

29 November 2007 Standard Patent Sealed

28 April 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004283241-Trans-2-enoyl-CoA reductase gene of euglena gracilis

2004283234-Use of genetic polymorphisms to predict drug-induced hepatotoxicity